<DOC>
	<DOCNO>NCT00830817</DOCNO>
	<brief_summary>The purpose study evaluate primarily safety tolerability secondarily efficacy topically apply WBI-1001 cream patient mild moderate psoriasis . Double-blind , randomize , placebo control study 36 patient , treat 28 day plus 7 day follow-up.in patient divide six cohort : Cohort 1 0.5 % QD ; Cohort 2 0.5 % BID ; Cohort 3 1.0 % QD ; Cohort 4 1.0 % BID ; Cohort 5 2.0 % QD ; Cohort 6 2.0 % BID.Efficacy assess PGA , target lesion assessment BSA . Safety assess vital sign , ECG , AEs Plasma PK via Cmin , Cmax , Tmax AUCo-t .</brief_summary>
	<brief_title>Double-Blind Study Topical WBI-1001 Cream Patients With Psoriasis</brief_title>
	<detailed_description>Patients initiate screen within 4 week commence study treatment . Based progression study , day 0 patient assign one six treatment Cohorts . Patients randomize treat area except face , scalp , groin genital area . Patients Cohort 1 treat one side thin layer active cream placebo ; absence significant AEs 14 day last treatment Cohort escalation next Cohort allow , Cohort respectively . During treatment period patient visit study centre weekly safety , tolerability efficacy assessment . On study visit day blood draws do 7.00 10.00am prior morning 's application cream . The study enrol healthy male female patient age 18-65 y.o . clinical diagnosis stable plaque psoriasis &gt; month affect maximum 6 % BSA minimum 0.5 % BSA side body minimum one plaque least 2x2 cm side exclude elbow knee .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>PGA score day 0 must 2,3 4 . In good overall health . Women child bear potential negative serum betahuman chorionic gonadotropin pregnancy test randomization Must prepare use adequate mean contraception Must lactating . Male partner female study must prepare use adequate mean contraception . Must comply study protocol attend visit . Provide write consent prior participate study . Spontaneously improve rapidly deteriorate psoriasis . Patients diseases ( especially dermatological , immunodeficiency neurological/psychiatric ) might interfere assessment plaque psoriasis . Systemic immunomodulatory therapy past 36 week , phototherapy past 4 week , various psoriatic chemotherapy beta blocker past 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Topical cream application</keyword>
	<keyword>Mild moderate psoriasis</keyword>
</DOC>